- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02592954
Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin
December 4, 2017 updated by: Johns Hopkins University
Adult participants will apply a broccoli sprout extract-jojoba oil compound to one arm every night under occlusion for 1 week.
Jojoba oil alone will be applied to the other arm.
At the end of 1 week, a 6mm punch biopsy will be taken from both arms and analyzed via polymerase chain reaction (PCR) and immunohistochemistry for differences in various skin proteins.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
10 adult volunteers, including African American, Caucasian, male and female participants, will be recruited from parents of patients seen in the pediatric dermatology clinic.
Each participant will receive 7ml of broccoli sprout extract (BSE) in jojoba oil, containing 3500nmol of sulforaphane (Please see the preparation of broccoli sprout extract below).
500nmol of sulforaphane will be applied each night.
The participants will apply the BSE-jojoba oil mixture over a circle, 3cm in diameter, on the upper arm every night for 7 consecutive nights.
The control arm will have only jojoba oil applied.
Both arms will be occluded with saran wrap every night.
After the seventh night, the volunteers will have a 6mm biopsy taken from each arm (2 total), performed by a dermatology resident.
The biopsies will be cleaned with alcohol, numbed with 0.5-1cc of 1% lidocaine with epinephrine, and closed with one 4-0 nylon nonabsorbable suture.
The biopsy site will be covered with Vaseline and a bandaid.
The area will be kept covered for 24 hours, after which it may be washed with soap and water and then recovered with Vaseline and a bandaid.
The suture will be removed 10-14 days after the procedure.
From the initial visit through the final visit for suture removal, we expect the duration of the trial to last approximately 1 month.
The participants will be told to avoid applying any topical medications or over the counter lotions or creams for the duration of the study and will also be told to wash with Dove soap in the shower.
They will also be advised to avoid a diet high in cruciferous plants such as broccoli, mustard, and horseradish.
The biopsy results will each be divided in half.
One half to be frozen for cryosectioning and immunofluorescence staining and the other half to be used for protein or RNA extraction for molecular assays (real time polymerase chain reaction and/or quantitative polymerase chain reaction for select messenger RNAs and western blotting for select protein antigens).
The levels of keratin 1, keratin 5, keratin 10, keratin 14, keratin 16, keratin 17, and Nrf2 will be studied with both immunofluorescence and RNA PCR.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to attend 3 visits at the designated times.
Exclusion Criteria:
- Pregnant
- Known allergy to broccoli, lidocaine, or epinephrine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Jojoba oil with broccoli sprout extract
500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
|
500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
|
|
Placebo Comparator: Jojoba oil
1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
|
1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immunohistochemistry
Time Frame: Within 1 month of skin biopsy
|
Immunohistochemistry of protein levels of keratin 1, keratin 5, keratin 10, keratin 14, keratin 16, keratin 17, and Nrf2
|
Within 1 month of skin biopsy
|
|
Real time- Polymerase Chain Reaction
Time Frame: Within 1 month of skin biopsy
|
Real time- Polymerase Chain Reaction of protein levels of keratin 1, keratin 5, keratin 10, keratin 14, keratin 16, keratin 17, and Nrf2
|
Within 1 month of skin biopsy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events
Time Frame: During the trial until 2 months after the trial ends
|
Any adverse events associated with topical application of the drug or placebo
|
During the trial until 2 months after the trial ends
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bernard Cohen, MD, Professor of Dermatology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
October 29, 2015
First Submitted That Met QC Criteria
October 29, 2015
First Posted (Estimate)
October 30, 2015
Study Record Updates
Last Update Posted (Actual)
December 6, 2017
Last Update Submitted That Met QC Criteria
December 4, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Pathological Conditions, Anatomical
- Skin Diseases, Genetic
- Skin Diseases, Vesiculobullous
- Nail Diseases
- Skin Abnormalities
- Abnormalities, Multiple
- Ectodermal Dysplasia
- Epidermolysis Bullosa
- Epidermolysis Bullosa Simplex
- Pachyonychia Congenita
- Nails, Malformed
Other Study ID Numbers
- BSE2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epidermolysis Bullosa Simplex
-
Castle Creek Pharmaceuticals, LLCCompletedDystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)United States
-
Centre Hospitalier Universitaire de NiceCompletedEpidermolysis Bullosa Simplex Dowling MearaFrance
-
TWi Biotechnology, Inc.Active, not recruitingGeneralized Epidermolysis Bullosa SimplexUnited States, Belgium, Spain, Taiwan, Israel, China, Australia, Philippines, Ireland, United Arab Emirates, India, Malaysia, Austria, Greece, Italy, Poland, South Korea, United Kingdom
-
Joyce TengRecruitingHealthy | Epidermolysis Bullosa | Genetic Skin Disease | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, JunctionalUnited States
-
ProgenaBiomeWithdrawnEpidermolysis Bullosa | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa SimplexUnited States
-
InMed Pharmaceuticals Inc.CompletedEpidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, Junctional | Kindler SyndromeFrance, Germany, Greece, Israel, Italy
-
Castle Creek Pharmaceuticals, LLCTerminatedEpidermolysis Bullosa SimplexUnited States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
-
Tel-Aviv Sourasky Medical CenterUnknownEpidermolysis Bullosa Simplex
-
Xinnate ABRecruitingDystrophic Epidermolysis Bullosa | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)France, Spain, Sweden, Greece, Italy
-
Castle Creek Pharmaceuticals, LLCCompletedEpidermolysis Bullosa | Epidermolysis Bullosa SimplexUnited States
Clinical Trials on Jojoba oil with broccoli sprout extract
-
Johns Hopkins UniversityCompleted
-
University of ArizonaNational Cancer Institute (NCI)CompletedCarcinoma in Situ | Head and Neck Cancer | Hyperplasia | Head and Neck Squamous Cell Carcinoma | HNSCC | Dysplasia | Tobacco-Related Carcinoma | Premalignant LesionUnited States
-
Pusan National University Yangsan HospitalRecruitingCognitive Dysfunction | Cognitive DeclineSouth Korea
-
National Cancer Institute (NCI)CompletedCigarette Smoking-Related Carcinoma | Tobacco-Related CarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)Completed
-
Fred Hutchinson Cancer CenterJohns Hopkins University; University of Washington; Cedars-Sinai Medical Center; VA Puget Sound Health Care System and other collaboratorsCompleted
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)CompletedBreast Cancer | Precancerous ConditionUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
TC Erciyes UniversityEnrolling by invitationAromatherapy in Hemodialysis Patients with ItchingTurkey
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; University of Pittsburgh; University of Minnesota; National... and other collaboratorsCompleted